Lipoprotein(a): The Most Dangerous Cardiovascular Risk Factor Most People Have Never Heard Of

Lp(a) is a lipoprotein particle with a structure similar to LDL but with an additional glycoprotein — apolipoprotein(a) [apo(a)] — covalently linked to ApoB-100 via a disulfide bond.[1] Apo(a) contains multiple kringle repeats, including a series of kringle IV type 2 (KIV-2) repeats that are highly polymorphic in copy number between individuals. This copy number variation is the primary determinant of Lp(a) plasma concentration: individuals with fewer KIV-2 repeats produce larger apo(a) isoforms but paradoxically lower plasma Lp(a) levels; those with higher repeat numbers produce smaller isoforms and higher Lp(a) levels.[2]

The structural similarity to plasminogen — Lp(a)'s kringle domains resemble plasminogen's lysine-binding sites — provides a mechanistic basis for Lp(a)'s dual proatherosclerotic and prothrombotic properties. Lp(a) competes with plasminogen for binding sites on fibrin clots, potentially inhibiting fibrinolysis and promoting thrombosis.[3]

Lp(a) plasma concentrations are approximately 70–90% heritable, with the LPA gene locus on chromosome 6q27 accounting for the majority of this variation.[4] Plasma levels range from less than 1 mg/dL to over 300 mg/dL across populations. The distribution is right-skewed and varies by ancestry: individuals of African descent have significantly higher median Lp(a) levels compared to individuals of European or Asian descent.[5]

Approximately 20% of the global population carries Lp(a) levels above 50 mg/dL (approximately 125 nmol/L) — the threshold most commonly associated with significantly elevated cardiovascular risk in major guidelines. This translates to approximately 1.4 billion affected individuals worldwide.[6]

The Copenhagen City Heart Study (Kamstrup et al., 2009) demonstrated that genetically elevated Lp(a) was associated with a hazard ratio of 1.6 for myocardial infarction, independent of LDL cholesterol, CRP, and conventional cardiovascular risk factors.[7] Critically, this study used a Mendelian randomization design — leveraging the randomness of genetic variation at the LPA locus as a natural experiment — to establish a causal relationship rather than mere correlation.

A meta-analysis by the Emerging Risk Factors Collaboration (n>200,000) confirmed that Lp(a) elevation was independently associated with coronary artery disease, ischemic stroke, and aortic stenosis.[8] The relationship appears dose-dependent, with risk increasing progressively above 30 mg/dL and most steeply above 50–75 mg/dL.

Notably, the relationship between Lp(a) and calcific aortic valve disease is particularly strong — a connection not shared by conventional LDL cholesterol. Elevated Lp(a) appears to promote valvular calcification through its lipid cargo and apo(a)-mediated inhibition of matrix metalloproteinases.[9]

The standard lipid panel measures total cholesterol mass, LDL cholesterol (calculated), HDL cholesterol, and triglycerides. Lp(a) is not reported. The cholesterol carried within Lp(a) particles is mathematically included in calculated LDL cholesterol, but the absolute Lp(a) concentration — the number that carries clinical meaning — is invisible.

A patient with LDL cholesterol of 95 mg/dL and Lp(a) of 180 mg/dL is classified as low-risk by standard lipid screening. Their actual lifelong cardiovascular risk is substantially elevated. This patient will complete annual physicals for years, receive reassurance from normal lipid panels, and potentially present with a first MI or aortic valve calcification as their initial clinical event.

Current guidelines from the European Atherosclerosis Society (EAS), the 2022 ACC/AHA guidelines, and the 2023 Canadian Cardiovascular Society guidelines all recommend measuring Lp(a) at least once in every adult's lifetime.[10] The measurement rationale is straightforward: Lp(a) is genetically determined, does not change meaningfully over a lifetime, and its discovery meaningfully reclassifies risk in a substantial proportion of patients.

Honesty is required here: there is currently no approved pharmacologic therapy that specifically targets and lowers Lp(a) in routine clinical practice.

The therapeutic landscape for Lp(a) is changing rapidly. Three RNA-targeting therapies are currently in Phase 3 cardiovascular outcome trials:

If Phase 3 outcome data confirm cardiovascular event reduction — expected within the next 2–5 years — the clinical management of elevated Lp(a) will be transformed. Identifying patients with elevated Lp(a) now positions them for emerging therapies and enables risk modification in the interim.

Lipoprotein(a) is a genetically determined, causally established, and eminently measurable cardiovascular risk factor that is present at pathologically elevated levels in approximately one in five adults and is invisible to standard lipid testing. The evidence base for its role in atherosclerotic cardiovascular disease, ischemic stroke, and calcific aortic valve disease is now strong enough to have driven formal guideline recommendations for universal lifetime testing.

The absence of an approved specific therapy does not diminish the value of testing. It intensifies it. Patients with elevated Lp(a) deserve to know — so they can optimize every other modifiable risk factor, so they can make informed decisions about imaging and statin intensity, and so they are positioned to benefit from the transformative therapies now in late-phase trials.

“Test it once. Know the number. Act accordingly.”